Registering for and monitoring the Louisiana Prescription Drug Monitoring Program (PMP) can help both Quality Payment Program (QPP) performance (avoiding a Medicare penalty) and compliance with new opioid legislation. Two of the 93 QPP Improvement Activities directly relate to the PMP and new Louisiana opioid law.
- Improvement Activity Number IA_PSPA_5 (Annual Registration in the PMP)
Annual registration by eligible clinician or group in the prescription drug monitoring program of the state where they practice. Activities that simply involve registration are not sufficient. MIPS eligible clinicians and groups must participate for a minimum of 6 months.
- Improvement Activity Number IA_PSPA_6 (Consultation of the PMP)
Clinicians would attest that, 60 percent for first year, or 75 percent for the second year, of consultation of prescription drug monitoring program prior to the issuance of a Controlled Substance Schedule II (CSII) opioid prescription that lasts for longer than three days
CMS intentionally left the descriptions broad and the documentation guidelines suggestive. What is imperative, however, is that providers keep consistent documentation supporting the activities they choose to report. Improvement Activities cannot be reported via claims, but the CMS attestation portal is a no cost reporting mechanism for eligible clinicians.
For assistance with Improvement Activities, reporting or general QPP participation, contact LAMMICO Practice Management Specialist, Natalie Cohen at email@example.com or 504.841.2727.
This is not legal advice, and is not intended to substitute for individualized business of financial judgment. It does not dictate exclusive methods, and is not applicable to all circumstances.